United Kingdom

Imperial College London

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Imperial College Advances Covid-19 Vaccine into Next Phase

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

Details:

Imperial College London in the UK has advanced its Covid-19 vaccine candidate into the next phase of the COVAC1 clinical trial following the success in the initial dose escalation phase involving 15 volunteers.

Imperial College London

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Imperial College London Begins Dosing in Covid-19 Vaccine Study

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

Based on a new self-amplifying RNA (saRNA) technology, the vaccine was found to be safe and generated promising evidence of an effective immune response in pre-clinical safety tests and animal studies.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Astrazeneca Gets Funding And Manufacturing Boost For UK Vaccine Programme

Lead Product(s): ChAdOx1 nCoV-19

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $81.3 million Upfront Cash: Undisclosed

Deal Type: Funding May 17, 2020

Details:

The Government has announced £65.5 million of new funding for the vaccine being developed at the Oxford Vaccine Group as coronavirus vaccine trials accelerate. If the Oxford vaccine is successful, AstraZeneca will deliver 100 million doses in total worldwide.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Astrazeneca Strikes Deal With Oxford University to Mass Produce Experimental COVID-19 Vaccine

Lead Product(s): ChAdOx1 nCoV-19

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Oxford University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 30, 2020

Details:

The collaboration aims at bringing to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Imperial College London

Imperial College Advances Covid-19 Vaccine into Next Phase

Imperial College London

Imperial College London Begins Dosing in Covid-19 Vaccine Study

AstraZeneca PLC

Astrazeneca Gets Funding And Manufacturing Boost For UK Vaccine Programme

AstraZeneca PLC

Astrazeneca Strikes Deal With Oxford University to Mass Produce Experimental COVID-19 Vaccine